Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Antiviral Res ; 192: 105105, 2021 08.
Article in English | MEDLINE | ID: mdl-34111505

ABSTRACT

We present here a case study of an antibody-engineering platform that selects, modifies, and assembles antibody parts to construct novel antibodies. A salient feature of this platform includes the role of amino acid networks in optimizing framework regions (FRs) and complementarity determining regions (CDRs) to engineer new antibodies with desired structure-function relationships. The details of this approach are described in the context of its utility in engineering ZAb_FLEP, a potent anti-Zika virus antibody. ZAb_FLEP comprises of distinct parts, including heavy chain and light chain FRs and CDRs, with engineered features such as loop lengths and optimal epitope-paratope contacts. We demonstrate, with different test antibodies derived from different FR-CDR combinations, that despite these test antibodies sharing high overall sequence similarity, they yield diverse functional readouts. Furthermore, we show that strategies relying on one dimensional sequence similarity-based analyses of antibodies miss important structural nuances of the FR-CDR relationship, which is effectively addressed by the amino acid networks approach of this platform.


Subject(s)
Antibodies, Viral/chemistry , Antiviral Agents/chemistry , Protein Engineering , Amino Acid Sequence , Antibodies, Viral/immunology , Antibodies, Viral/pharmacology , Antibody Affinity , Antiviral Agents/immunology , Antiviral Agents/pharmacology , Binding Sites, Antibody , Complementarity Determining Regions/chemistry , Computational Biology , Drug Design , Epitopes , Immunoglobulin Fab Fragments/chemistry , Immunoglobulin Fab Fragments/immunology , Molecular Docking Simulation , Neutralization Tests , Zika Virus/drug effects , Zika Virus/immunology
2.
Bioorg Med Chem Lett ; 28(13): 2324-2327, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29801997

ABSTRACT

To identify a potent and selective nucleoside inhibitor of dengue virus RNA-dependent RNA polymerase, a series of 2'- and/or 4'-ribose sugar modified uridine nucleoside phosphoramidate prodrugs and their corresponding triphosphates were synthesized and evaluated. Replacement of 2'-OH with 2'-F led to be a poor substrate for both dengue virus and human mitochondrial RNA polymerases. Instead of 2'-fluorination, the introduction of fluorine at the ribose 4'-position was found not to affect the inhibition of the dengue virus polymerase with a reduction in uptake by mitochondrial RNA polymerase. 2'-C-ethynyl-4'-F-uridine phosphoramidate prodrug displayed potent anti-dengue virus activity in the primary human peripheral blood mononuclear cell-based assay with no significant cytotoxicity in human hepatocellular liver carcinoma cell lines and no mitochondrial toxicity in the cell-based assay using human prostate cancer cell lines.


Subject(s)
Antiviral Agents/pharmacology , Enzyme Inhibitors/pharmacology , Prodrugs/pharmacology , RNA-Dependent RNA Polymerase/antagonists & inhibitors , Uridine Monophosphate/analogs & derivatives , Uridine Monophosphate/pharmacology , Antiviral Agents/chemistry , Antiviral Agents/toxicity , Dengue Virus/enzymology , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/toxicity , Hep G2 Cells , Humans , Leukocytes, Mononuclear/virology , Molecular Structure , Mononuclear Phagocyte System/virology , Prodrugs/chemistry , Prodrugs/toxicity , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...